Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HKMPY and 80,000+ other tickers.
See exactly how HKMPY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HKMPY and 80,000+ other tickers.
Hikma Pharmaceuticals PLC is a global pharmaceutical company that specializes in the development, production, commercialization, and distribution of a wide array of generic, branded, and in-licensed medicines. These pharmaceuticals are provided in various final dosage forms, including solid, semi-solid, liquid, and injectable formats. The company's business activities are organized into three core divisions: Injectables, Generics, and Branded products. The Injectables division primarily supplies generic injectable medications for hospital use. Its Generics segment focuses on offering oral and…
Hikma Pharmaceuticals PLC (HKMPY) Q2 2026 Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q2 2026 Earnings Call Prepared Remarks Transcript
LONDON, June 4, 2026 /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc., (Hikma) offered the following comments on today's unanimous decision by the Supreme Court of the United States effectively ending Amarin's patent infringement litigation against the company. "Hikma has long fought for patients and their access to safe, high-quality, and affordable medicines," said Sam Park, General Counsel, Hikma.
Cleveland and Columbus, Ohio, June 01, 2026 (GLOBE NEWSWIRE) -- COLUMBUS and CLEVELAND, Ohio - Ohio Governor Mike DeWine, along with Hikma Pharmaceuticals, JobsOhio, the City of Bedford, and other state and local partners, today announced plans for a significant expansion of Hikma's manufacturing operations in Ohio, reinforcing the company's commitment to the state's growing pharmaceutical and biomanufacturing industry.
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript